NCT00235482View on ClinicalTrials.gov

Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02)

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

November 8, 2005

Primary Completion Date

April 21, 2006

Study Completion Date

April 21, 2006

Conditions
Malignant Melanoma
Interventions
DRUG

Coxsackievirus A21

Trial Locations (1)

2298

Melanoma Unit, Mater Misericordiae Hospital, Newcastle

Sponsors

Lead Sponsor

Viralytics
All Listed Sponsors
lead

Viralytics

INDUSTRY

NCT00235482 - Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma (PXS-X02) | Biotech Hunter | Biotech Hunter